Immuneering
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 68
- Market Cap
- $33.5M
- Introduction
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung CancerMalignant Melanoma (Cutaneous)
- Interventions
- Drug: IMM-6-415
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Immuneering Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT06208124
- Locations
- ๐บ๐ธ
Honor Health Research Institute, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธSarah Cannon Research Institute, Denver, Colorado, United States
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Malignant Melanoma (Cutaneous)Advanced Solid TumorNon-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma
- Interventions
- Drug: IMM-1-104 Monotherapy (Treatment Group A)Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)Drug: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Immuneering Corporation
- Target Recruit Count
- 210
- Registration Number
- NCT05585320
- Locations
- ๐บ๐ธ
NEXT Oncology, Fairfax, Virginia, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of California San Diego, San Diego, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath